<DOC>
	<DOCNO>NCT01609933</DOCNO>
	<brief_summary>A study evaluate safety effect treatment experimental antiviral drug combination peginterferon alpha-2a ribavirin people hepatitis C virus respond treatment previous AbbVie/Abbott combination study .</brief_summary>
	<brief_title>A Study Evaluate Safety Effect Treatment With Experimental Antiviral Drugs Combination With Peginterferon Alpha-2a Ribavirin People With Hepatitis C Virus Who Did Not Respond Treatment Previous AbbVie/Abbott Combination Study</brief_title>
	<detailed_description>A study evaluate safety effect treatment experimental antiviral drug combination peginterferon alpha-2a ribavirin people hepatitis C virus respond treatment previous AbbVie/Abbott combination study . The study test safety effect alternative treatment 48 week .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Main Inclusion : To enrol protocol , subject must meet follow inclusion criterion : Subject must experience virologic failure define previous AbbVie/Abbott direct act antiviral combination trial . Female subject childbearing potential must willing use two effective form birth control ( include oral contraceptive contraceptive contain ethinyl estradiol ) receive study drug 7 month ( per local ribavirin label ) stop study drug Males must surgically sterile male partner agree practice two effective form birth control throughout course study , start Study Day 1 7 month ( per local ribavirin label ) last dose study drug , unless abstinent sexual intercourse . Subject must consider appropriate candidate peginterferon alpha2a , ribavirin , ABT450/r ABT267 therapy opinion investigator . Subject infected HCV genotype 1 screening . Subjects diagnosed cirrhosis must also meet follow criterion : Compensated cirrhosis define ChildPugh score â‰¤ 6 Screening . Absence hepatocellular carcinoma base negative ultrasound , compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) perform within 3 month prior Screening Screening period . In subject prior null partial response pegIFN/RBV treatment time prior prescreening study prior failure pegIFN/RBV plus telaprevir , presence variant relative appropriate prototypic reference sequence ( H77 1a Con1 1b ) follow position : NS3 155 , 156 , 168 ; NS5A 28 , 29 , 30 , 31 , 32 , 58 , 93 . Females pregnant plan become pregnant , breastfeeding , male whose partner pregnant plan become pregnant within 7 month ( per local RBV label ) last dose RBV . Use know strong inducer ( e.g. , phenobarbital , rifampin , carbamazepine , St. John 's Wort ) CYP3A within 2 week prior study drug administration . Use medication contraindicate use peginterferon alpha2a , RBV ritonavir within 2 week prior study drug administration . Prior enter study , subject must able safely discontinue contraindicated medication switch acceptable alternative supervision investigator . Discontinuation antiviral therapy due intolerance DAA RBVassociated adverse event previous AbbVie/Abbott DAA combination study . Subjects compensate cirrhosis must also meet follow criterion : Any current past clinical evidence ChildPugh B C Classification clinical history liver decompensation ascites ( noted physical exam ) , variceal bleed hepatic encephalopathy . Serum AlphaFetoprotein ( sAFP ) &gt; 100 ng/mL Screening . A screen ultrasound suspicious hepatocellular carcinoma confirm subsequent CT scan MRI screening period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>71 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatitis C Genotype 1</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>HCV</keyword>
</DOC>